Advanced pulmonary sarcoidosis☆

被引:0
|
作者
Jeny, Florence [1 ]
Valeyre, Dominique [2 ]
Lower, Elyse E. [3 ]
Baughman, Robert P. [3 ]
机构
[1] Univ Sorbonne Paris Nord, Avicenne Univ Hosp, APHP, INSERM,Dept Pulmonol,UMR 1272, Bobigny, France
[2] Univ Sorbonne Paris Nord, Grp Hosp Paris St Joseph, INSERM, UMR 1272, Paris, France
[3] UNIV CINCINNATI, Dept Med, Med Ctr, CINCINNATI, OH USA
关键词
Pulmonary sarcoidosis; Pulmonary fibrosis; Pulmonary arterial hypertension; Prednisone; Infliximab; UNITED-STATES; CLINICAL CHARACTERISTICS; INFLAMMATORY ACTIVITY; RESPIRATORY-FAILURE; NECROSIS-FACTOR; INCREASED RISK; HYPERTENSION; MORTALITY; THERAPY; ASPERGILLOSIS;
D O I
10.1016/j.jaut.2025.103397
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Sarcoidosis affects the lungs in most patients. Manifestations of pulmonary sarcoidosis range from asymptomatic to death. Approximately a quarter of sarcoidosis patients develop chronic pulmonary disease. Advanced pulmonary sarcoidosis patients are those who have progressive disease and are at risk for significant morbidity and mortality. There are several features associated with advanced pulmonary disease: pulmonary fibrosis, pulmonary hypertension, chronic pulmonary inflammation, and/or complications of disease or therapy. Large retrospective studies have identified pulmonary fibrosis and pulmonary hypertension as the major causes of respiratory failure and death in pulmonary sarcoidosis. The high-resolution computer tomography scan (HRCT) and echocardiogram are key methods in screening for pulmonary hypertension and pulmonary fibrosis. Therapy for chronic pulmonary inflammation has been the major focus in chronic disease. However, treatment for pulmonary hypertension has been studied in sarcoidosis. To date, treatment studies for sarcoidosis associated progressive pulmonary fibrosis have been underpowered to demonstrate clear cut benefit of anti-fibrotic agents.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Novel insights in fibrotic pulmonary sarcoidosis
    Comes, Alessia
    Sofia, Carmelo
    Richeldi, Luca
    CURRENT OPINION IN PULMONARY MEDICINE, 2022, 28 (05) : 478 - 484
  • [42] Challenges in Cardiac and Pulmonary Sarcoidosis JACC State-of-the-Art Review
    Trivieri, Maria Giovanna
    Spagnolo, Paolo
    Birnie, David
    Liu, Peter
    Drake, Wonder
    Kovacic, Jason C.
    Baughman, Robert
    Fayad, Zahi A.
    Judson, Marc A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (16) : 1878 - 1901
  • [43] Fibrotic Pulmonary Sarcoidosis
    Nunes, Hilario
    Brillet, Pierre -Yves
    Bernaudin, Jean-Francois
    Gille, Thomas
    Valeyre, Dominique
    Jeny, Florence
    CLINICS IN CHEST MEDICINE, 2024, 45 (01) : 199 - 212
  • [44] Pulmonary sarcoidosis: an update
    Ramachandraiah, Vidya
    Aronow, Wilbert
    Chandy, Dipak
    POSTGRADUATE MEDICINE, 2017, 129 (01) : 149 - 158
  • [45] Pulmonary hypertension complicating pulmonary sarcoidosis
    Huitema, M. P.
    Grutters, J. C.
    Rensing, B. J. W. M.
    Reesink, H. J.
    Post, M. C.
    NETHERLANDS HEART JOURNAL, 2016, 24 (06) : 390 - 399
  • [46] Diagnosis of pulmonary sarcoidosis
    Israel-Biet, Dominique
    Valeyre, Dominique
    CURRENT OPINION IN PULMONARY MEDICINE, 2013, 19 (05) : 510 - 515
  • [47] The treatment of pulmonary sarcoidosis
    Judson, Marc A.
    RESPIRATORY MEDICINE, 2012, 106 (10) : 1351 - 1361
  • [48] PULMONARY FIBROSIS IN SARCOIDOSIS
    Asif, Huda
    Neto, Manuel Lessa Ribeiro
    Culver, Daniel Arnold
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2023, 40 (03)
  • [49] The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis
    Salvador, Maria Caridad Mata
    Francesqui, Joel
    Sellares, Jacobo
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (10) : 1317 - 1324
  • [50] Sarcoidosis-associated pulmonary fibrosis: joining the dots
    Bandyopadhyay, Debabrata
    Mirsaeidi, Mehdi S.
    EUROPEAN RESPIRATORY REVIEW, 2023, 32 (169)